Rezolute Stock Climbs 12% as FDA Offers Path for Ersodetug

Edgen Stock

·Mar 25 2026, 15:25

Share to

Share to

Copy link

Key Takeaways

Rezolute's stock gained 12% after the company announced a constructive outcome from a meeting with the U.S. Food and Drug Administration concerning its lead drug candidate, ersodetug. The FDA's decision to review data from a Phase 3 trial that previously failed its primary endpoint provides a potential regulatory path forward, significantly boosting investor confidence.

Rezolute stock (RZLT) advanced 12% on March 25 after the company reported a positive update following its meeting with the FDA.
The FDA agreed to review the full dataset for ersodetug's sunRIZE trial, even though the study failed to meet its primary endpoint in December 2025.
This development revives hopes for the congenital hyperinsulinism treatment, with Rezolute expecting a further program update in the second half of 2026.

FDA Offers Lifeline After Phase 3 Trial Failure

Shares of Rezolute (Nasdaq: RZLT) increased 12% on March 25 after the company secured a critical opportunity for its lead drug candidate, ersodetug. The gains followed a March 24 announcement detailing a productive meeting with the U.S. Food and Drug Administration (FDA) held on March 17. This development revived investor optimism that had diminished when the drug's Phase 3 sunRIZE study for congenital hyperinsulinism failed to meet its primary endpoint in December 2025. Rezolute has maintained that the trial's outcome was compromised by behavioral factors in the study group rather than a lack of drug efficacy.

Rezolute to Submit Full Data for FDA Review

Instead of dismissing the program, the FDA acknowledged the clinical trial's complexities and encouraged Rezolute to submit the complete study reports and analysis datasets for the agency's independent evaluation. This provides a clear, albeit preliminary, path forward for a drug program that investors had largely written off. The FDA's willingness to conduct a thorough review signals that ersodetug may still have a route to market approval. Rezolute stated it expects to provide another update on the program's status in the second half of 2026 following the agency's review.

We are extremely encouraged by the outcome of our meeting with FDA including the fact that, while acknowledging their feedback was preliminary, the agency did not dismiss sunRIZE outright on the basis of not meeting its primary endpoint.

— Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute.